Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin

The pancreatic β‐cell hormone, amylin, is absent or reduced in individuals with type I diabetes mellitus and in many insulin‐treated patients with type II diabetes. Amylin replacement therapy may be beneficial in these individuals, but the pharmaceutically inconvenient physicochemical properties of native human amylin led to the development instead of the amylin agonist, [Pro25,28,29]human amylin, or pramlintide (formerly designated AC137). Here we compare for rat amylin, human amylin and pramlintide, receptor binding and biological actions in rats in vivo and in rat soleus muscle. In the rat, the spectrum of actions and pharmacokinetic and pharmacodynamic properties of pramlintide are either very similar to, or indistinguishable from, those of rat or human amylin. © 1996 Wiley‐Liss, Inc.

[1]  G. Cooper,et al.  Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro , 1988, Nature.

[2]  T. Rink,et al.  Dose response characteristics for the hyperglycemic, hyperlactemic, hypotensive and hypocalcemic actions of amylin and calcitonin gene-related peptide-I (CGRP alpha) in the fasted, anaesthetized rat. , 1993, Life sciences.

[3]  G. Cooper,et al.  Amylin injection causes elevated plasma lactate and glucose in the rat , 1991, FEBS letters.

[4]  G. Thorbecke,et al.  Biology of germinal centers in lymphoid tissue , 1994 .

[5]  F. Greenwood,et al.  Preparation of Iodine-131 Labelled Human Growth Hormone of High Specific Activity , 1962, Nature.

[6]  C. Bogardus,et al.  Evidence for Linkage Between a Region on Chromosome 1p and the Acute Insulin Response in Pima Indians , 1995, Diabetes.

[7]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Silvestre,et al.  Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas , 1993, Regulatory Peptides.

[9]  J. Holder,et al.  Repeat Treatment of Obese Mice With BRL 49653, a New Potent Insulin Sensitizer, Enhances Insulin Action in White Adipocytes: Association With Increased Insulin Binding and Cell-Surface GLUT4 as Measured by Photoaffinity Labeling , 1995, Diabetes.

[10]  J. Rothbard,et al.  Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  W. Born,et al.  Comparison of a Calcitonin Gene‐Related Peptide Receptor in a Human Neuroblastoma Cell Line (SK‐N‐MC) and a Calcitonin Receptor in a Human Breast Carcinoma Cell Line (T47D) a , 1992, Annals of the New York Academy of Sciences.

[12]  R. Unger,et al.  Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. , 1990, The Journal of clinical investigation.

[13]  J. Morley,et al.  Amylin decreases food intake in mice , 1991, Peptides.

[14]  S. L. Andersen,et al.  Calcitonin gene-related peptide stimulates active Na(+)-K+ transport in rat soleus muscle. , 1993, American Journal of Physiology.

[15]  T. Rink,et al.  Amylin regulation of carbohydrate metabolism. , 1995, Biochemical Society transactions.

[16]  R. Quirion,et al.  Autoradiographic distribution and receptor binding profile of [125I]Bolton Hunter-rat amylin binding sites in the rat brain. , 1994, The Journal of pharmacology and experimental therapeutics.

[17]  John A. Martin,et al.  Differential Calcitonin Gene‐Related Peptide (CGRP) and Amylin Binding Sites in Nucleus Accumbens and Lung: Potential Models for Studying CGRP/Amylin Receptor Subtypes , 1995, Journal of neurochemistry.

[18]  C. Betsholtz,et al.  Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. , 1989, Experimental cell research.

[19]  T. Williams,et al.  The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit. , 1990, The American journal of pathology.

[20]  W. Colburn,et al.  Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin Analogue , 1995, Diabetes Care.

[21]  T. Rink,et al.  High affinity amylin binding sites in rat brain. , 1993, Molecular pharmacology.

[22]  H. Datta,et al.  Amylin‐amide: a new bone‐conserving peptide from the pancreas , 1990, Experimental physiology.

[23]  T. Westfall,et al.  Amylin‐Induced Relaxation of the Perfused Mesenteric Arterial Bed: Meditation by Calcitonin Gene‐Related Peptide Receptors , 1995, Journal of cardiovascular pharmacology.

[24]  J. Eisman,et al.  Calcitonin and 1,25-dihydroxyvitamin D3 receptors in human breast cancer cell lines. , 1980, Cancer research.

[25]  G. Paxinos,et al.  In vitro autoradiographic localization of amylin binding sites in rat brain , 1994, Neuroscience.